114 related articles for article (PubMed ID: 2443622)
1. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
Howell SB; Zimm S; Markman M; Abramson IS; Cleary S; Lucas WE; Weiss RJ
J Clin Oncol; 1987 Oct; 5(10):1607-12. PubMed ID: 2443622
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
Piver MS; Recio FO; Baker TR; Driscoll D
Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
[TBL] [Abstract][Full Text] [Related]
3. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
5. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
Recio FO; Piver MS; Hempling RE; Driscoll DL
Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
9. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
Markman M; Howell SB; Lucas WE; Pfeifle CE; Green MR
J Clin Oncol; 1984 Dec; 2(12):1321-6. PubMed ID: 6542584
[TBL] [Abstract][Full Text] [Related]
10. Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.
Markman M; Cleary S; Lucas W; Weiss R; Howell SB
Cancer Treat Rep; 1986 Jun; 70(6):755-60. PubMed ID: 2425962
[TBL] [Abstract][Full Text] [Related]
11. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
13. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
Barakat RR; Fennelly D; Pizzuto F; Venkatraman ES; Brown C; Curtin JP
Eur J Gynaecol Oncol; 1997; 18(3):161-3. PubMed ID: 9174826
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Yordan EL; Eriksson J; Lewis JL
J Clin Oncol; 1991 Feb; 9(2):204-10. PubMed ID: 1988569
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
18. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-based chemotherapy in advanced ovarian cancer: initial experience in an Indian set-up.
Charak BS; Agarwala S; Gopal R; Advani SH; Nadkarni KS; Pai VR; Saikia TK; Desai PB
Indian J Cancer; 1989 Jun; 26(2):85-91. PubMed ID: 2592001
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]